OEP Products

Precise Products, Experienced Distribution

 

OEP produces and markets a diverse range of products from generics to specialty pharma. Our portfolio focuses on complex modified release oral and cytotoxic injectables.

Our products are made in Taiwan, a Trade Agreement Act (TAA)-compliant country, allowing us to sell directly to the U.S. government.

US Product Portfolio

ANDAs

Immediate Releases

Carisoprodol
Miglitol
Vancomycin
Glyburide
Pitavastatin*
Ezetimibe
1PC114
1PD101
1PC115
  • Formulation
  • Pilot BE
  • Pivotal BE
  • Approved
  • Marketed
  • Formulation
  • Pilot BE
  • Pivotal BE
  • Approved
  • Marketed

Controlled Releases

Rivastigmine
2PN101
1PCO23
1PL105
  • Formulation
  • Pilot BE
  • Pivotal BE
  • Approved
  • Marketed
  • Formulation
  • Pilot BE
  • Pivotal BE
  • Approved
  • Marketed

505 (b)(2)s

Immediate Releases

P + E **
3PA001
  • Formulation
  • Pivotal BE
  • Clinical 
  • Approved
  • Marketed
  • Formulation
  • Pivotal BE
  • Clinical 
  • Approved
  • Marketed

Controlled Releases

Methydur**
1PN114**
11111 **
  • Formulation
  • Pivotal BE
  • Clinical 
  • Approved
  • Marketed
  • Formulation
  • Pivotal BE
  • Clinical 
  • Approved
  • Marketed
ANDAs Progress Bar 505(b)(2)s Progress bar
* denotes First to File || **denotes products only marketed in Taiwan

 

 

Asia Product Portfolio

Zulitor
Trokendi
Pitator
Navelbine
Methydur
Cardiovascular
Neurology
Diabetes
Respiratory
Oncology